Skip to main content Over 2024-2025, the Australian Government has introduced several Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) updates to improve the access to diagnosis and treatment for people living with endometriosis. These changes reflect growing recognition of endometriosis as a chronic, debilitating condition affecting nearly 1 in 7 Australians.
PBS Listings: Affordable Access to Medications
- Dienogest (Visanne)
Listed on the PBS in December 2024, Dienogest is a progestin-only oral medication used in endometriosis treatment. Previously costing around $750 per year, its PBS listing has halved the price, making long-term management more affordable. It now costs $31.60 for 28 tablets.
- Ryeqo
From 1 May 2025, Ryeqo became available on the PBS for moderate to severe endometriosis. This once-daily tablet combines relugolix, estradiol, and norethisterone acetate. The cost has dropped from $2700 to as little as $92–$380 annually, offering relief to those previously unable to afford it and costing $31.60 for 28 tablets.
- Slinda
Slinda, a progestogen-only contraceptive, was also included in the 2025 PBS update. It is suitable for patients who cannot take estrogen, supporting broader reproductive health needs.
MBS Listings: Expanded Imaging Access
Advanced Pelvic Ultrasound
Starting 1 November 2025, Medicare will subsidise specialised pelvic ultrasounds for suspected or confirmed endometriosis. These scans, which were previously only available privately, are crucial for diagnosing deep infiltrating endometriosis, reducing delays and improving treatment planning.
These PBS and MBS updates mark an important step toward more equitable endometriosis care in Australia by significantly reducing out-of-pocket costs and improving access to both diagnosis and long-term management. Those affected with endometriosis are encouraged to speak with their GP or gynaecologist to discuss whether these options are suitable for their individual needs.